Skip to Content
 

VICC toll-free number 1-877-936-8422

Brain Tumors and Neurologic Cancers

The focus of the Vanderbilt Brain Tumor Center is to provide comprehensive compassionate care to patients with brain tumors. We have assembled a dedicated team of clinicians and scientists who are committed to finding a cure for brain cancer. We are passionate in this pursuit.

Clinical Trials for Neurologic / Brain Cancers

9 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Supportive Care

NRGNEUCC001

07/14/2016

A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy with or without Hippocampal Avoidance in Patients with Brain Metastases

Treatment

VICCNEU1688

04/28/2017

A Randomized Phase 2 Single Blind Study of Temozolomide Plus Radiation Therapy Combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (Tumor O6-methylguanine DNA methyltransferase) Glioblastoma

Treatment

VICCNEU1644

04/28/2017

A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumor O-6-methylguanine DNA methyltransferase) Glioblastoma

Treatment

ECOGNEUA221208

01/18/2017

Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis after Radiosurgery for Brain Metastases

Treatment

VICCNEU1670

12/08/2016

A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma that Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy - STELLAR Study

Treatment

NRGNEUR0631

07/15/2016

Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis

Treatment

VICCMD15110

04/05/2016

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Treatment

ECOGNEUA071401

12/18/2015

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Treatment

VICCMD1403

06/02/2014

An Open Label, Phase II Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification